Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
+ e' Y" l9 S( F* v d7 y2 x7 M7 @( A% W8 F
d4 Q, j! N$ j! k! @
Sub-category:
! ^; P( I+ Z+ I* f2 P$ NMolecular Targets
' \3 q! ^6 M' {. _: D" N+ j# ]- x9 [2 W1 p' E% [ }" y
/ h& k( J9 j& t2 C/ e: o
Category:) v8 w5 z: w4 ?$ Y
Tumor Biology 4 D0 O$ a. X0 O1 Z" G
/ l6 I( I3 v2 m6 t$ ~ n$ j: y* E4 N8 V# v1 j
Meeting:) G \$ U% @* Z/ W7 k
2011 ASCO Annual Meeting
3 N1 A$ n u2 r0 [3 r4 a4 l4 c, m& H$ s" k
0 a U9 {* \6 t! k* ?
Session Type and Session Title:
- O; ?4 w4 U3 X+ P, hPoster Discussion Session, Tumor Biology
9 e, S. d; ]# n4 y' S- N$ m& i9 ~ U: J( O' M7 Y4 j& S7 V
# c1 s8 b j; A/ T( G( x
Abstract No:
+ R I) \: o' m2 A6 g6 Y: U! q10517 P2 |4 R" R: t) @* r
9 S% @4 g" O# h- X$ Y. G g e" z- J
Citation:
% a7 O, \8 ^7 p* OJ Clin Oncol 29: 2011 (suppl; abstr 10517)
) S- [+ U* ^; C1 \3 K4 Q5 n3 r7 k0 v: N. v- }
% B, T3 m% q! u. w% C( K+ Y( \
Author(s):
; ]8 E6 F5 G2 b; B1 q) z& H) o! xJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ; y2 `0 Q: T" |
7 H; L ^# L; U4 Z3 q; b( A( ] e8 p0 k5 r* P0 [8 |
6 k: \4 \/ p/ D3 E" d4 v8 `$ FAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
4 R. \ @# A2 ^4 Y9 X4 C, }/ o8 R& t7 M; H4 @
Abstract Disclosures
, ~" D) N: I* N& m2 r4 E0 o: C& T* J6 p
Abstract:" |; J' L' e" v7 @! q, b
- m; U+ q: x! O8 F& K% U, [
- s8 k* ]+ H+ M: l/ n) ~8 [2 [
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.3 B) `6 b- Z* L4 g* i
. \/ t5 {; Z3 \; T7 Y4 `) ?
6 p2 K: g$ U+ Q |
& a- U' X6 m7 s: b3 S
显身卡
